Dr. Talapatra is a partner and intellectual property lawyer with Foley & Lardner LLP. Dr. Talapatra’s practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. Dr. Talapatra also has a unique perspective on European companies with ties of the U.S., having lived in The Netherlands and frequently returning to the continent. In addition to patent counseling and prosecution matters, he has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the "1st-Ever" Pharma AIA Ruling (Amneal Pharma Inc v. Supernus Pharma Inc.). Some of Dr. Talapatra's exemplary patent cases include Chatterjee v Tabor (interference proceeding re DNA polymerase); Keygene NV vs Floragenex, Inc. (patent infringement action) and Biota Scientific Ltd. vs Kappos (appeal of USPTO decision re obviousness of pharmaceutical formulation). He is a member of the Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Life Sciences Industry Team.
Dr. Talapatra has authored several legal and scientific publications and is frequently quoted in FDA Week and Inside Health Policy. He also regularly lectures on patent matters, most recently at the 2016 FCBA Global Outreach Series (Paris).
Dr. Talapatra earned his law degree from The George Washington University. He received his Ph.D. in cell and molecular biology from the University of Pennsylvania. He also holds an M.S. in biochemistry and molecular biology from the University of Chicago and a B.S. in chemistry from the University of California at Los Angeles. Dr. Talapatra’s graduate work in cancer biology was conducted under the guidance of Dr. Craig Thompson.
Dr. Talapatra is admitted to practice in Virginia and the District of Columbia and before the United States Patent and Trademark Office.
Select Speaking Engagements